BCB-276

all catalysts(0)

nothing on the calendar yet

News(3)

• BrainChild Bio targets deadly pediatric brain cancer with $116M series A
  BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
  biospace · 26d ago
• BrainChild hauls in $116M to make cell therapies for childhood brain cancers
  Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
  biopharma_dive · 26d ago
• BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
  A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.
  fiercebiotech · 27d ago